You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀:石藥(01093.HK)去年純利遜預期5% 維持「中性」評級
阿思達克 03-30 16:37
瑞銀發表報告表示,石藥集團(01093.HK)去年收入按年升25%、純利按年增長21%,指純利低於該行原預期5%,主要是通用仿製藥銷售低於預期(遜預期11%)及散裝藥銷售遜預期4%。

該行指,維持石藥「中性」投資評級,及目標價20.7元,此按現金流折現率作估值。瑞銀稱,石藥其中一個核心增長引擎,白蛋白紫杉醇(albumin-bound PTX)獲納入第二輪集中採購,但在今年4至5月將面對約三分之二的降價;大幅降價料將抵銷獲納入集中採購帶來的潛在銷量增長。同時該行亦會留意石藥創新藥品在今明兩年推出情況。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account